The Week in Review: December 1 – December 8, 2017

Friday, December 8, 2017 News Recap: URGENT BC Patient and Caregiver Input Request: Vosevi. We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Personal Stories This week we have two great stories of triumphing over HepC: Aidain’s ‘I will never forget the day I found out I had hepatitis c’, and Patric...

URGENT BC Patient and Caregiver Input Request: Vosevi

URGENT BC Patient and Caregiver Input Request: We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Check out the background information in links below to see the results that have been achieved in clinical trials to date. Gilead’s “SOF-VEL-VOX” combo is pan-genotypic (works for all genotypes). One pill

The Week in Review: October 20 – October 27, 2017

Friday, October 27, 2017 News Recap: Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6. We need to hear your voice by November 8, 2017!  AbbVie’s “GP” combo is pan-genotypic (works for all genotypes). Liver Meeting 2017: I’m A HCV Patient – Show Me What I Need to Know! Why reinvent the wheel? The good folks over at HCV New Drugs have put together this great overview o...

Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6

URGENT BC Patient and Caregiver Input Request: We need to hear your voice! Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6.  AbbVie’s “GP” combo is pan-genotypic (works for all genotypes).  Check out the background information in links below to learn the results that have been achieved in clinical trials to date. You will see that the cure rates across all genotypes are hig

143,000 First Nations to switch to tailored B.C. Pharmacare plan

Status First Nations people in B.C. will begin health coverage under a tailored version of the provincial pharmacare system on Sunday, marking the first time a province takes over health care coverage for that group. Since 1979, First Nations people in B.C. have been covered under Canada Health’s Non-Insured Health Benefits program, which provides coverage for prescription medications, dental and medical supplies. The FNHA version of Pharmacare, called

The Week in Review: March 17, 2017 – March 24, 2017

Friday, March 24, 2017 News Recap Well, if you've been up to our site and seen the daily news posts you will have seen that new drug access policies have now come into effect in BC and Quebec, as well as Ontario. It looks like the slate is the same for these 3 provinces, and we are listing what's available in BC so you can make sense of it.  For more information on the expanded access criteria in Quebec see here, and in particular the note from CD. ...

British Columbia lists EPCLUSA™ on public drug plan to treat all six genotypes of chronic hepatitis C infection

-- British Columbia Also Broadens Access for Patients with Less Advanced Disease Who Have Other Health Conditions -- MISSISSAUGA, ON, March 21, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced, effective March 21, 2017, British Columbia will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C ...

The Week in Review: Feb 24, 2017 – March 3, 2017

Friday, March 3, 2017 News Recap Top of the news is an upcoming conference/webinar to be held in Prince George that will examine the question:  “Does care for hepatitis C in rural/remote areas differ from that in urban parts of our province, and if so, how?”  On March 6th (11 am – noon), researchers from the BC Centre for Disease Control (BCCDC) will try to answer these questions. Núria Chapinal, PhD, an epidemiologist in BCCDC’s Clinical Prevention ...

The Week in Review: Feb 17, 2017 – Feb 24, 2017

Friday, February 24, 2017 News Recap Better Public Access to New HepC Meds Announced in Canada This week the pan-Canadian Pharmaceutical Alliance (pCPA), on behalf of participating federal, provincial and territorial public drug plans, concluded successful negotiations with three drug manufacturers to help jurisdictions expand access to publicly funded medications for the treatment of chronic hepatitis C. What this Means: Immediately following th...

‘No One Left Behind!’ — Update from Pacific Hepatitis C Network on Recent PharmaCare Developments

Pacific Hepatitis C Network is very happy to learn that effective March 21, an extensive list of hepatitis C treatments will be available through BC PharmaCare – at far better prices than they previously had been. The high cost of hepatitis C treatment has effectively restricted the numbers of people living with hepatitis C who could access treatment. Even with lower prices, those restrictions will remain in place until next year. Come March 2018, those r